4.2 Article

Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment

期刊

EUROPEAN JOURNAL OF HAEMATOLOGY
卷 92, 期 3, 页码 195-203

出版社

WILEY
DOI: 10.1111/ejh.12228

关键词

PD-L1; acute myeloid leukemia; PD-1; IFN

资金

  1. German Cancer Foundation (Deutsche Krebshilfe e.V.) [10-2204]
  2. Dutch Cancer Foundation (KWF) [2008-3988]

向作者/读者索取更多资源

IntroductionWhile current treatment for acute myeloid leukemia is characterized by high response rates, patients' long-term outcome is still disappointing, due to frequent relapse and ineligibility of the often elderly patients for stem cell transplantation approaches. Considerable efforts have, thus, been made to incorporate immunotherapeutic approaches in the acute myeloid leukemia (AML) consolidation, with so far disappointing clinical benefit. The B7 family ligand programmed-death receptor-ligand 1 (PD-L1, B7-H1, CD274) has been recently described (with conflicting results) to be expressed on AML blast cells, and interaction with its receptor on T cells, programmed death receptor-1 (PD-1, CD279), has been shown to suppress T-cell functions and to allow survival of dormant AML cells in animal models. Design and MethodsIn this work, we analyzed freshly isolated myeloid precursor cells from healthy donors and from AML patients for PD-L1 expression with or without interferon- exposure at different time points during their treatment. ResultsWhile without IFN exposure, only minor differences were observed, we found IFN--induced PD-L1 expression most prominent after initial treatment and independent of treatment outcome. ConclusionsOur observations support the recently suggested PD-L1-mediated adaptive immune resistance and argue for a targeting of the PD-L1/PD-1 pathway during the consolidation phase of AML treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据